Liying Zhang, MD, PhD

Director, Diagnostic Molecular Genetics Laboratory; Associate Director, Molecular Genetic Pathology Fellowship Program
Liying Zhang, MD, PhD

I am a board-certified molecular geneticist with a special interest in cancer genetics. As the director of the Diagnostic Molecular Genetics Laboratory at Memorial Sloan-Kettering, I am responsible for supervising the molecular diagnostic testing for inherited disorders — in particular the inherited forms of breast, ovarian, colorectal, and other types of cancers. The identification of  genetic alterations enables better medical management options that can reduce risk through prevention or early detection. I have led the development and implementation of various new diagnostic genetic tests. I also oversee strategic planning for the laboratory's technologies, instrumentation, staffing, budget, and regulatory issues.

I am a member of the Clinical Testing Advisory Group (CTAG) at Memorial Sloan-Kettering. The role of CTAG is to evaluate the strength and quality of the clinical evidence supporting new assays and to determine whether the available evidence supports a uniform approach for providing these tests to our patients. With the availability of next-generation sequencing (NGS) technology, I am actively bringing in innovative, cutting-edge clinical molecular diagnostic tests to provide physicians with the information they need to better care for their patients.

Location
Phone
212-639-5170
Clinical Expertise

Diagnostic Molecular Genetics

Languages Spoken
English
Education

MD, Peking University (China); PhD, The Johns Hopkins University; MS (Bioinformatics), The Johns Hopkins University

Fellowships

Memorial Sloan-Kettering Cancer Center

Board Certifications

Clinical Molecular Genetics

See My Colleagues in:
Publications by Liying Zhang
Shia J, Zhang L, Shike M, Guo M, Stadler Z, Xiong X, Tang LH, Vakiani E, Katabi N, Wang H, Bacares R, Ruggeri J, Boland CR, Ladanyi M, Klimstra DS. Secondary mutation in a coding monomucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol. 2012 Aug 24. doi10.1038/modpathol.2012.138.
 
Stadler ZK, Salo-Mullen E, Zhang L, Shia J, Bacares R, Power DG, Weiser M, Coit D, Robson ME, Offit K, Schattner M. Juveile Polyposis Syndrome Presenting with Familial Gastric Cancer and Massive Gastric Polyposis. J Clin Oncol. 2012 Jul 23.
 

Karamurzin Y, Zeng Z, Stadler ZK, Zhang L, Ouansafi I, Al-Amadie HA, Sempous C, Saltz LB, Soslow RA, O'Reilly EM, Paty PD, Coit DG, Shia J, Klimstra DS. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.  Hum Pathol. 2012 Apr 17.

Zhang L, Chen L, Bacares R, Ruggeri JM, Somar J, Kemel Y, Stadler ZK, Offit K. BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. Breast Cancer Res Treat. 2011, Dec; 130(3): 1051-6 

Shah M, Salo-Mullen E, Stadler Z, Ruggeri J, Mirander M, Pristyazhnyuk Y, Zhang L. De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer. Clinical Genetics Jun 11, 2011;

Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, Offit K, Foulkes WD, Robson ME, Tischkowitz M. Germline PALB2 mutation analysis in breast-pancreas cancer families. J Med Genet 2011.

Topics Recommended by Liying Zhang

Making an Appointment

We will assist you or your referring doctor to make an appointment with one of our physicians.